Potentially delayed but certainly not dead....unless you are taking the view, not unreasonably I guess, that the label following a successful REDUCE IT trial will be much, much wider than an Anchor label.
1. NCE- take a look at the patents.
2. BP- probably.
3. FDA is there to be shot at if they breach the SPA and should be shot....no pussy footing around and Amarin has the fact pattern and resources to make the FDA uncomfortable.